Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials
TL;DR
Bio-Path Holdings' innovative DNAbilize® technology and diverse pipeline, including prexigebersen for AML, positions it as a potential leader in RNAi therapeutics, offering a competitive edge in biotech investments.
Bio-Path Holdings utilizes its DNAbilize® platform to deliver antisense oligonucleotides with enhanced stability and uptake, currently testing prexigebersen in Phase 2 trials for AML and exploring treatments for solid tumors and metabolic diseases.
Bio-Path Holdings' research into RNAi therapeutics like prexigebersen could revolutionize treatment for AML, solid tumors, and metabolic diseases, significantly improving patient outcomes and quality of life.
Discover how Bio-Path Holdings' DNAbilize® technology is breaking barriers in drug delivery, with promising candidates for leukemia, solid tumors, and even obesity and diabetes treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
Bio-Path Holdings, Inc., a clinical-stage biotechnology company, is making notable progress with its RNA interference (RNAi) therapeutics, leveraging its proprietary DNAbilize® platform. This technology, which enhances drug stability and cellular uptake while reducing toxicity, is at the heart of the company's innovative approach to treating complex diseases. With lead candidate prexigebersen (BP1001) in Phase 2 trials for acute myeloid leukemia (AML) and BP1001-A showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes, Bio-Path is at the forefront of developing targeted therapies.
The company's pipeline also includes BP1002, targeting the Bcl-2 protein for blood cancers and solid tumors, and BP1003, a STAT3 inhibitor aimed at pancreatic cancer, currently in preclinical development. The achievement of a third preclinical milestone for BP1001-A underscores its potential in addressing obesity in type 2 diabetes patients, a significant health challenge worldwide.
Bio-Path's strategic relationships, including its original technology platform licensed from The MD Anderson Cancer Center, and a strong intellectual property position, bolster its standing in the competitive biotechnology landscape. Despite a reported cash on hand of $122,000 as of March 31, 2025, and the need for additional funding to meet 2025 operational requirements, the company's undervaluation compared to peers highlights its growth potential. With numerous drug candidates in the pipeline and key milestones on the horizon, Bio-Path Holdings is poised to make a lasting impact on the treatment of cancers and metabolic diseases.
Curated from Reportable
